France’s Sanofi buys Ablynx for $4.8 billion in biotech mergers and acquisitions boom

01/29/2018 - CNBC - Reuters - 

  • Sanofi beat Novo Nordisk to the deal.
  • The move marks the drugmaker's second big deal this month after buying Bioverativ.
  • Sanofi said Monday it would pay 45 euros per share in cash for Ablynx, a premium of 21.2 percent over its closing price Friday.